- Home
- SAVA vs STEM Comparison
SAVA vs STEM Comparison
Compare SAVA & STEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- STEM
- Stock Information
- Founded
- SAVA 1998
- STEM 2009
- Country
- SAVA United States
- STEM United States
- Employees
- SAVA N/A
- STEM N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- STEM Computer Software: Prepackaged Software
- Sector
- SAVA Health Care
- STEM Technology
- Exchange
- SAVA Nasdaq
- STEM Nasdaq
- Market Cap
- SAVA 213.0M
- STEM 198.4M
- IPO Year
- SAVA N/A
- STEM N/A
- Fundamental
- Price
- SAVA $3.82
- STEM $23.81
- Analyst Decision
- SAVA Buy
- STEM Hold
- Analyst Count
- SAVA 2
- STEM 7
- Target Price
- SAVA $5.00
- STEM $12.14
- AVG Volume (30 Days)
- SAVA 3.1M
- STEM 442.1K
- Earning Date
- SAVA 11-07-2025
- STEM 10-29-2025
- Dividend Yield
- SAVA N/A
- STEM N/A
- EPS Growth
- SAVA N/A
- STEM N/A
- EPS
- SAVA N/A
- STEM N/A
- Revenue
- SAVA N/A
- STEM $156,002,000.00
- Revenue This Year
- SAVA N/A
- STEM $4.85
- Revenue Next Year
- SAVA N/A
- STEM $12.66
- P/E Ratio
- SAVA N/A
- STEM N/A
- Revenue Growth
- SAVA N/A
- STEM N/A
- 52 Week Low
- SAVA $1.15
- STEM $5.81
- 52 Week High
- SAVA $33.98
- STEM $33.60
- Technical
- Relative Strength Index (RSI)
- SAVA 53.58
- STEM 54.84
- Support Level
- SAVA $3.62
- STEM $19.76
- Resistance Level
- SAVA $4.69
- STEM $26.30
- Average True Range (ATR)
- SAVA 0.39
- STEM 3.19
- MACD
- SAVA -0.08
- STEM -0.52
- Stochastic Oscillator
- SAVA 26.42
- STEM 31.66
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.